reports
- Jonathan Moreland
TELA Bio to Announce First Quarter 2025 Financial Results
TELA Bio to Announce First Quarter 2025 Financial Results MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. First Quarter Earnings Conference Call and Webcast DetailsInvestors...
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sust...
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgrou...
- Jonathan Moreland
XPL SOLITARIO ZINC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
TTSH TILE SHOP HOLDINGS INC.
STAA STAAR SURGICAL CO.
SIG SIGNET JEWELERS LIMITED
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
RGP RESOURCES CONNECTION INC.
PBPB POTBELLY CORP.
PBF PBF ENERGY INC. CLASS A
CVGW CALAVO GROWERS INC.
CRMD CORMEDIX INC.
CRM SALESFORCE.COM INC.
CMC COMMERCIAL METALS COMPANY
CDXS CODEXIS
APA.. APA CORP.
AB ALLIANCEBERNSTEIN HOLDING L.P.
FLWS 1-800-FLOWERS.COM CL A
GWRS GLOBAL WATER RESOURCES
JELD JELD-WEN HOLDING INC.
SVRA SAVARA
WGO WINNEBAGO INDUSTRIES INC.
PNBK PATRIOT NATIONAL BANCORP
FF FIRST MINING GOLD
DOMO DOMO INCORPORATED
FUND ROYCE FOCUS TRUST
FGBI INC.
VEL FIRST GUARANTY BANCSHARES
ZYME VELOCITY COMPOSITES
RZLT ZYMEWORKS INC.
WOOF REZOLUTE
UAN INC.
VSCO PETCO HEALTH AND WELLNESS
BTMD CVR PARTNERS LP
EWTX VICTORIA'S SECRET & CO
TEAF HAYMAKER ACQUISITION CORP III
JMSB EDGEWISE THERAPEUTICS INC
ERNA ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
GTE JOHN MARSHALL BANCORP INC
SSII ETERNA THERAPEUTICS INC.
CATX GRAN TIERRA ENERGY INC.
ADVM SS INNOVATIONS INTERNATIONAL INC
SUNS PERSPECTIVE THERAPEUTICS
BNTC INC.
FG ADVERUM BIOTECHNOLOGIES INC.
ALMU SUNRISE REALTY TRUST
FTLF BENITEC BIOPHARMA INC
ECF F AND G ANNUITIES AND LIFE
INC.
AELUMA
INC.
FITLIFE BRANDS INC.
ELLSWORTH FUND LTD
- Jonathan Moreland
PBF PBF ENERGY INC. CLASS A
CVGW CALAVO GROWERS INC.
CRMD CORMEDIX INC.
CDXS CODEXIS
WGO WINNEBAGO INDUSTRIES INC.
UBX UNITY BIOTECHNOLOGY
FGBI FIRST GUARANTY BANCSHARES
PCB PACIFIC CITY FINANCIAL CORP
APA APA CORPORATION
NUVB NUVATION BIO INC (A)
FTCI FTC SOLAR
BTMD INC.
TEAF HAYMAKER ACQUISITION CORP III
BTM ECOFIN SUSTAINABLE AND SOCIAL IMPACT TERM FUND
STSFF BITCOIN DEPOT INC
ECF SMARTSTOP SELF STORAGE REIT
INC.
ELLSWORTH FUND LTD
- Jonathan Moreland
XPL SOLITARIO ZINC
UEPS NET 1 U.E.P.S. TECHNOLOGIES INC.
STAA STAAR SURGICAL CO.
SAIC SCIENCE APPLICATIONS INTERNATIONAL CORP.
MGPI MGP INGREDIENTS INC.
CRMD CORMEDIX INC.
FLWS 1-800-FLOWERS.COM CL A
JELD JELD-WEN HOLDING INC.
WGO WINNEBAGO INDUSTRIES INC.
FGBI FIRST GUARANTY BANCSHARES
ZYME ZYMEWORKS INC.
PCB PACIFIC CITY FINANCIAL CORP
CTGO CONTANGO ORE INC.
BTMD HAYMAKER ACQUISITION CORP III
SSII SS INNOVATIONS INTERNATIONAL INC
ADVM ADVERUM BIOTECHNOLOGIES INC.
NYC NEW YORK CITY REIT
BNTC INC.
FTLF BENITEC BIOPHARMA INC
FITLIFE BRANDS INC.
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these employees options to purchase an aggregate of 31,000 shares of the Company’s common stock with an exercise price of $12.49, the closing trading price of the Company’s common stock on the Nasd...
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtu...
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET. A live webcast of the presentation and fireside chats is expected to be accessible in the Events section of the C...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® P...
TELA Bio Announces U.S. Commercial Launch of Larger Sizes of OviTex® PRS for Plastic and Reconstructive Surgery The OviTex PRS portfolio now includes a larger option than any human acellular dermal matrix product on the market MALVERN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction solutions, today announced the U.S. launch of larger sizes of OviTex PRS Reinforced Tissue Matrix, the only tissue-based device reinforced with polymer suture embroidery specifically engineered for plastic...
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights Delivered revenue of $17.6 million in the fourth quarter and $69.3 million for the full year 2024, representing growth of 4% and 19%, respectively, over the corresponding periods of 2023;Increased demand for O...
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Pr...
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial Phase 2 trial of Descartes-08 in systemic lupus erythematosus ongoing with expected data readout in 2H25 Company expects to initiate Phase 2 pediatric basket trial of Decartes-08 in select autoimmune indications in 2H25 Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $214.3...
Cartesian Therapeutics Announces New Employment Inducement Grant
Cartesian Therapeutics Announces New Employment Inducement Grant FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company’s common stock with an exercise price of $17.50, the closing trading price of the Company’s common stock on the Nasdaq Global Mar...
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Resul...
TELA Bio to Announce Fourth Quarter and Full Year 2024 Financial Results MALVERN, Pa., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report fourth quarter and full year 2024 financial results on Thursday, March 20, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Fourth Quarter Earnings Conference ...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 7,200 shares of its common stock to thirteen newly-hired employees, with a grant date of February 19, 2025 (the "Grant Date"). The restricted stock units were grante...
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian Therapeutics to Participate in Upcoming Investor Conferences FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in February and March: A fireside chat at the H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference at 1:00 p.m. ET on Tuesday, February 25, 2025A presentation at the TD Cowen 45th Annual Health Care Conference...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On February 3, 2025, the Company issued to these employees options to purchase an aggregate of 168,360 shares of the Company’s common stock with an exercise price of $19.89, the closing trading price of the Company’s common stock on ...
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agree...
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis Trial on track to commence in 1H25 FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company’s planned Phase 3 AURORA...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pu...
Cartesian Therapeutics Highlights Progress and 2025 Strategic Prioriti...
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25 Deepening responses observed over time in Descartes-08-treated participants in Phase 2b trial in myasthenia gravis; Safety profile continues to support outpatient administration based on updated data shared in December 2024 Phase 2 systemic lupus erythematosus (SLE) trial of Descartes-08 ongoing with expected data readout in 2H25 Cash resources expected to support pla...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to three new employees. On January 2, 2025, the Company issued to these employees options to purchase an aggregate of 19,324 shares of the Company’s common stock with an exercise price of $16.93, the closing trading price of the Company’s common stock on t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.